CA Patent

CA2785822C — Methods of providing weight loss therapy in patients with major depression

Assigned to Nalpropion Pharmaceuticals LLC · Expires 2019-06-25 · 7y expired

What this patent protects

This application pertains to the use of naltrexone and bupropion in the provision of weight loss therapy to an overweight or obese patient suffering from major depressive disorder.

USPTO Abstract

This application pertains to the use of naltrexone and bupropion in the provision of weight loss therapy to an overweight or obese patient suffering from major depressive disorder.

Drugs covered by this patent

Patent Metadata

Patent number: CA2785822C
Jurisdiction: CA
Classification: —
Expires: 2019-06-25
Drug substance claim: No
Drug product claim: No
Assignee: Nalpropion Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.